1. Repeatability of MRI Biomarkers in Nonalcoholic Fatty Liver Disease: The NIMBLE Consortium.
- Author
-
Fowler, Kathryn J, Venkatesh, Sudhakar K, Obuchowski, Nancy, Middleton, Michael S, Chen, Jun, Pepin, Kay, Magnuson, Jessica, Brown, Kathy J, Batakis, Danielle, Henderson, Walter C, Shankar, Sudha S, Kamphaus, Tania N, Pasek, Alex, Calle, Roberto A, Sanyal, Arun J, Loomba, Rohit, Ehman, Richard, Samir, Anthony E, Sirlin, Claude B, and Sherlock, Sarah P
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Chronic Liver Disease and Cirrhosis ,Clinical Research ,Biomedical Imaging ,Hepatitis ,Liver Disease ,Digestive Diseases ,4.2 Evaluation of markers and technologies ,4.1 Discovery and preclinical testing of markers and technologies ,2.1 Biological and endogenous factors ,Oral and gastrointestinal ,Adult ,Female ,Humans ,Middle Aged ,Biomarkers ,Cross-Sectional Studies ,Elasticity Imaging Techniques ,Fibrosis ,Liver ,Magnetic Resonance Imaging ,Non-alcoholic Fatty Liver Disease ,Prospective Studies ,Medical and Health Sciences ,Nuclear Medicine & Medical Imaging ,Clinical sciences - Abstract
Background There is a need for reliable noninvasive methods for diagnosing and monitoring nonalcoholic fatty liver disease (NAFLD). Thus, the multidisciplinary Non-invasive Biomarkers of Metabolic Liver disease (NIMBLE) consortium was formed to identify and advance the regulatory qualification of NAFLD imaging biomarkers. Purpose To determine the different-day same-scanner repeatability coefficient of liver MRI biomarkers in patients with NAFLD at risk for steatohepatitis. Materials and Methods NIMBLE 1.2 is a prospective, observational, single-center short-term cross-sectional study (October 2021 to June 2022) in adults with NAFLD across a spectrum of low, intermediate, and high likelihood of advanced fibrosis as determined according to the fibrosis based on four factors (FIB-4) index. Participants underwent up to seven MRI examinations across two visits less than or equal to 7 days apart. Standardized imaging protocols were implemented with six MRI scanners from three vendors at both 1.5 T and 3 T, with central analysis of the data performed by an independent reading center (University of California, San Diego). Trained analysts, who were blinded to clinical data, measured the MRI proton density fat fraction (PDFF), liver stiffness at MR elastography (MRE), and visceral adipose tissue (VAT) for each participant. Point estimates and CIs were calculated using χ2 distribution and statistical modeling for pooled repeatability measures. Results A total of 17 participants (mean age, 58 years ± 8.5 [SD]; 10 female) were included, of which seven (41.2%), six (35.3%), and four (23.5%) participants had a low, intermediate, or high likelihood of advanced fibrosis, respectively. The different-day same-scanner mean measurements were 13%-14% for PDFF, 6.6 L for VAT, and 3.15 kPa for two-dimensional MRE stiffness. The different-day same-scanner repeatability coefficients were 0.22 L (95% CI: 0.17, 0.29) for VAT, 0.75 kPa (95% CI: 0.6, 0.99) for MRE stiffness, 1.19% (95% CI: 0.96, 1.61) for MRI PDFF using magnitude reconstruction, 1.56% (95% CI: 1.26, 2.07) for MRI PDFF using complex reconstruction, and 19.7% (95% CI: 15.8, 26.2) for three-dimensional MRE shear modulus. Conclusion This preliminary study suggests that thresholds of 1.2%-1.6%, 0.22 L, and 0.75 kPa for MRI PDFF, VAT, and MRE, respectively, should be used to discern measurement error from real change in patients with NAFLD. ClinicalTrials.gov registration no. NCT05081427 © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Kozaka and Matsui in this issue.
- Published
- 2023